Per 100/25 mcg inhalation powd Fluticasone furoate 100 mcg, vilanterol 25 mcg. Per 200/25 mcg inhalation powd Fluticasone furoate 200 mcg, vilanterol 25 mcg
Indications/Uses
Maintenance treatment of asthma & airflow obstruction in patients w/ COPD including chronic bronchitis &/or emphysema & to reduce exacerbations of COPD in patients w/ an exacerbation history.
Asthma Adult & adolescents ≥12 yr Recommended dose: 1 inhalation once daily either morning or evening but at the same time everyday. Initially 100/25 mcg dose should be considered for patients required a low to mid dose & 200/25 mcg for higher dose of inhaled corticosteroid in combination w/ a long acting β2-agonist. COPD Adult Recommended dose: 1 inhalation of 100/25 mcg dose once daily. Moderate or severe hepatic impairment Max dose: 100/25 mcg.
Hepatic impairment. Do not use in the treatment of acute asthma symptoms or acute exacerbation in COPD. Do not stop therapy w/o physician supervision. Paradoxical bronchospasm. Severe CV disease. Pulmonary TB or in chronic or untreated infections. Risk of pneumonia in current smokers, w/ history of prior pneumonia, a BMI <25 kg/m2 & FEV1 <50%. Pregnancy & lactation. Childn <12 yr.
R03AK10 - vilanterol and fluticasone furoate ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Sign Out
